Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

Main Article Content

Jonathan Silverberg
Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC

Andrew Pink
St. John?s Institute of Dermatology, Guy?s and St. Thomas? Hospitals, London, UK

Christina Olsen
LEO Pharma A/S, Ballerup, Denmark

Stephan Weidinger
Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

Keywords

Atopic Dermatitis, Tralokinumab, Topical Corticosteroids

Abstract

Abstract not available.

References

1. Nutten S. Ann Nutr Metab 2015; 66(Suppl 1): 8–16.

2. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

3. Eckert L et al. J Am Acad Dermatol 2017; 77: 274–279.e273.

4. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

5. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

6. Bieber T. Allergy 2020; 75: 54–62.

7. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

8. Eichenfield LF et al. J Am Acad Dermatol 2014; 71: 116–132.

9. Boguniewicz M et al. J Allergy Clin Immunol Pract 2017; 5: 1519–1531.

10. Popovic B et al. J Mol Biol 2017; 429: 208–219.

11. Weidinger S et al. Oral presentation at the American Academy of Dermatology Virtual Meeting,
2020.

12. Choi JY et al. Br J Dermatol 2020; 182: 1017–25.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.99

Article Details

How to Cite
[1]
Silverberg, J., Pink, A., Olsen, C. and Weidinger, S. 2020. Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s99. DOI:https://doi.org/10.25251/skin.4.supp.99.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 > >>